Gastrointestinal Stromal Tumor in a Patient with Neurofibromatosis Type 1 That Was Successfully Treated with Regorafenib

Intern Med. 2019 Jul 1;58(13):1865-1870. doi: 10.2169/internalmedicine.2321-18. Epub 2019 Mar 28.

Abstract

An unconscious 55-year-old man with a history of neurofibromatosis type 1 (NF1) was transported to the emergency department and was diagnosed with acute renal failure owing to a large bladder tumor. A submucosal tumor was also identified in the duodenum. The patient was diagnosed with a primary gastrointestinal stromal tumor (GIST) of the bladder and duodenum. After six cycles of regorafenib therapy, 18F-fluorodeoxyglucose accumulation in the duodenal GIST on positron emission tomography-computed tomography (PET-CT) showed a partial metabolic response. Currently, no standard drug therapy for unresectable or relapsed NF1-associated GIST has been established. Regorafenib may thus be considered as and appropriate initial therapy.

Keywords: gastrointestinal stromal tumor; neurofibromatosis type 1; regorafenib; tyrosine kinase inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Duodenum / pathology*
  • Enzyme Inhibitors / therapeutic use*
  • Gastrointestinal Stromal Tumors / diagnostic imaging
  • Gastrointestinal Stromal Tumors / drug therapy*
  • Gastrointestinal Stromal Tumors / pathology*
  • Gastrointestinal Stromal Tumors / physiopathology
  • Humans
  • Male
  • Middle Aged
  • Neurofibromatosis 1 / diagnostic imaging
  • Neurofibromatosis 1 / etiology
  • Neurofibromatosis 1 / pathology*
  • Phenylurea Compounds / therapeutic use*
  • Positron Emission Tomography Computed Tomography
  • Pyridines / therapeutic use*
  • Treatment Outcome
  • Urinary Bladder Neoplasms / pathology*

Substances

  • Enzyme Inhibitors
  • Phenylurea Compounds
  • Pyridines
  • regorafenib